Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 51Lung Neoplasms 40Carcinoma, Non-Small-Cell Lung 28Neoplasm Metastasis 25Brain Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Pancreatic Neoplasms 21Breast Neoplasms 20Glioma 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 17Multiple Myeloma 16Urinary Bladder Neoplasms 13Colorectal Neoplasms 13Carcinoma, Renal Cell 13Mouth Neoplasms 12Oropharyngeal Neoplasms 11Lymphoma, Mantle-Cell 11Carcinoma 11Triple Negative Breast Neoplasms 10Melanoma 10Leukemia, Lymphocytic, Chronic, B-Cell 10Laryngeal Neoplasms 10Ovarian Neoplasms 9Nasopharyngeal Carcinoma 8Lymphoma, Follicular 8Leukemia, Myeloid, Acute 8Hypopharyngeal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7

Interventions

neratinib 1Sampling Studies 1Radiotherapy, Adjuvant 1Positron Emission Tomography Computed Tomography 1Mastectomy, Segmental 1Magnetic Resonance Spectroscopy 1Liquid Biopsy 1High-Energy Shock Waves 1Drug Therapy 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Lobular × Magnetic Resonance Spectroscopy × Clear all
NCT05919108 2025-09-09

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
30 enrolled

Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡